Small molecule-based therapy for p53-deficient tumors: Tumor suppressor GET1 suppresses & increases the expression of DNp63α & IAPP (Amylin), respectively, and induces regression of p53-mutated human tumors via down regulation of its target gene, 9/May/2015, 12.10 pm

Natural product-based therapy for T2DM: Hibiscus extract enhances insulin secretion by increasing glucagon-like peptide-1 secretion via up regulation of its target gene, 9/May/2015, 10.05 am
May 9, 2015
Interleukin-based therapy for pulmonary diabetic cardiomyopathy: IL-1β inhibits the development of diabetic cardiomyopathy via down regulation of its target gene Foxo1, 9/May/2015, 12.17 pm
May 9, 2015
Show all

A recent study from the Department of Molecular and Cellular Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA [2] Department of Translational Molecular Pathology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA [3] Graduate School of Biomedical Sciences, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA [4] Metastasis Research Center, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA shows that“IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo.” This study was published in the 29 January  2015 issue of the Journal “Nature” (the no.1 journal in Science with an impact factor of 42) by Prof. Flores ER, Venkatanarayan A and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Small molecule-based therapy for p53-deficient tumors: Tumor suppressor GET1 suppresses &  increases the expression of DNp63α &  IAPP (Amylin), respectively, and induces regression of p53-mutated human tumors via down regulation of its target gene.

Significance:  Cancer suppressor p53 is mutated in more than 50% of cancers of different origin, while its pathway is altered in about 80% of tumors. This study suggests a therapeutic strategy as to how p53-deficient or mutant p53 expressing human cancers can be cured by suppressing its “oncogenic version of homologous protein p63” such as DNp63α. 

It has been shown earlier that GET1 functions as a tumor suppressor.  This study suggests that, GET1, by suppressing the expression of its target gene, it may decrease the expression of DNp63α; and thereby increase the expression of IAPP (Amylin). Thus, pharmacological formulations encompassing “GET1 activators”  can be used to inhibit the progression of p53-deficient human tumors.

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Web: http://genomediscovery.org

CitationBoominathan, Small molecule-based therapy for p53-deficient tumors: GET1 suppresses &  increases the expression of DNp63α &  IAPP (Amylin), respectively, and induces regression of p53-mutated human tumors via down regulation of its target gene, 9/May/2015, 12.14 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Undisclosed information: How GET1 suppresses the expression of DNp63α and increases the expression of IAPP

* Research cooperation

Comments are closed.